
Christian Maurer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9282739/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial. European Journal of Cancer, 2021, 144, 351-359.	2.8	2
2	The prognostic performance of PREDICT+ in patients (pts) with HER2-positive (HER2+) early-stage breast cancer (EBC) Journal of Clinical Oncology, 2021, 39, 524-524.	1.6	1
3	Second primary malignancies in treated and untreated patients with chronic lymphocytic leukemia. American Journal of Hematology, 2021, 96, E457-E460.	4.1	3
4	Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy. Leukemia, 2020, 34, 1177-1181.	7.2	6
5	Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis. ESMO Open, 2020, 5, e000842.	4.5	16
6	Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma. Annals of Hematology, 2020, 99, 1429-1440.	1.8	33
7	Long Term Followâ€up Data and Healthâ€Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG). HemaSphere, 2020, 4, e336.	2.7	31
8	Rapid response infrastructure for pandemic preparedness in a tertiary care hospital: lessons learned from the COVID-19 outbreak in Cologne, Germany, February to March 2020. Eurosurveillance, 2020, 25, .	7.0	18
9	Endocrine therapy and palbociclib within a compassionate use program in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer. Breast, 2018, 39, 14-18.	2.2	14
10	Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis. Cancer Treatment Reviews, 2018, 62, 123-132.	7.7	16
11	Risk factors for the development of brain metastases in patients with HER2-positive breast cancer. ESMO Open, 2018, 3, e000440.	4.5	27
12	Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis. ESMO Open, 2018, 3, e000361.	4.5	49
13	Impact of body mass index (BMI) and weight change after treatment in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Secondary analysis of the ALTTO BIG 2-06 trial Journal of Clinical Oncology, 2018, 36, 10067-10067.	1.6	2
14	PARP inhibitors (PARPi) for the treatment of <i>BRCA</i> mutated HER2-negative (HER2-) metastatic breast cancer (MBC) patients: A systematic review and meta-analysis Journal of Clinical Oncology, 2018, 36, e13098-e13098.	1.6	1
15	B-cell acute lymphoblastic leukemia (B-ALL) in CLL patients treated with lenalidomide Journal of Clinical Oncology, 2018, 36, 7531-7531.	1.6	0
16	New agents for endocrine resistance in breast cancer. Breast, 2017, 34, 1-11.	2.2	22
17	Male breast cancer: finding the way in this uncommon path. ESMO Open, 2017, 2, e000169.	4.5	1
18	Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia. European Journal of Haematology, 2016, 97, 253-260.	2.2	19

#	Article	IF	CITATIONS
19	First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncology, The, 2016, 17, 928-942.	10.7	529
20	Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood, 2016, 127, 208-215.	1.4	571